http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010204286-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3869a2a04c0cb9a1fbc0e3dbe5d97e94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c486163fb58d44499b34759db6046e2c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate | 2010-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2d2dcbe83e7a4ecc0ea960e438dc909 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdb115448cc8b513c1bf77fd113b0c8b |
| publicationDate | 2010-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2010204286-A1 |
| titleOfInvention | Method for reducing gastrointestinal adverse effects of cytotoxic agents |
| abstract | A method for moderating a gastrointestinal adverse effect induced by at least one cytotoxic agent, for example ionizing radiation and/or at least one chemotherapeutic agent, in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor or a compound selected from (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylaminol-4-methylpentanoic acid (ORE1001), pharmaceutically acceptable salts thereof and prodrugs thereof. A method for treating a cancerous condition in a subject comprises administering to the subject (a) at least one cytotoxic anticancer agent, for example ionizing radiation and/or at least one chemotherapeutic agent; and (b) an ACE2 inhibitor or a compound selected from ORE1001, pharmaceutically acceptable salts thereof and prodrugs thereof in an amount effective to moderate a gastrointestinal adverse effect induced by the anticancer agent. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11337909-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019106085-A1 |
| priorityDate | 2009-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1225.